• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Climb Bio Inc.

    4/24/26 4:15:27 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLYM alert in real time by email
    DEFA14A 1 d86565ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under § 240.14a-12

     

     

    Climb Bio, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     

     


     

    LOGO

     

    PROXY TABULATOR P.O. BOX 8016, CARY, NC 27512-9903

     

    LOGO

       LOGO

     

     

     

    Climb Bio, Inc.

     

    Annual Meeting of Stockholders

     

    Friday, June 5, 2026 9:00 AM, Eastern Time

     

    Annual Meeting to be held exclusively via the Internet - please visit www.proxydocs.com/CLYM for more details.

     

    You must register to attend the meeting online and/or participate at www.proxydocs.com/CLYM

     

     

    For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/CLYM

     

    To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

     

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet.

     

    If you want to receive a paper or email copy of the proxy materials, you must request one on or before May 25, 2026. There is no charge to you for requesting a copy. Unless requested, you will not otherwise receive a paper or email copy.

         

     

    Proxy Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K

     

    Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders To Be Held on June 5, 2026 For Stockholders of Record as of April 7, 2026.

     

    To request paper copies of the proxy materials, use one of the following methods.

     

      LOGO

     

    Internet:

    www.investorelections.com/CLYM

     

      LOGO

     

    Call:

    1-866-648-8133

     

      LOGO

     

    Email:

    paper@investorelections.com

     

    * If requesting a copy of the proxy materials by email, please send a blank email with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your email requesting a copy of the proxy materials.

     

         

     

      LOGO

     
       

    Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

     

    SEE REVERSE FOR FULL AGENDA    

    Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO    Climb Bio, Inc. Annual Meeting of Stockholders

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

    FOR EACH OF THE NOMINEES IN PROPOSAL 1 AND

    FOR PROPOSAL 2, PROPOSAL 3 AND PROPOSAL 4.

     

        

     

    PROPOSAL

     

    1.    The election of two Class II directors, each to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his respective successor has been duly elected and qualified;
       1.01 Alexander (Bo) Cumbo
       1.02 Douglas Williams, Ph.D.
    2.    The ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;
    3.    The approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended, relating to the removal of directors for “cause”;
    4.    The approval of an amendment to our 2021 Equity Incentive Plan to amend the provision providing for an automatic share pool increase to include prefunded warrants in the calculation of the annual increase; and
    5.    The transaction of any other business that may properly come before the 2026 Annual Meeting or any adjournment or postponement thereof.
    Get the next $CLYM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLYM

    DatePrice TargetRatingAnalyst
    5/5/2026$22.00Buy
    Chardan Capital Markets
    4/15/2026$18.00Outperform
    Mizuho
    3/24/2026$26.00Buy
    B. Riley Securities
    3/18/2026$17.00Buy
    Truist
    3/11/2026$25.00Strong Buy
    Raymond James
    3/5/2026$12.00Outperform
    Wedbush
    2/13/2026$23.00Overweight
    Piper Sandler
    10/16/2025Outperform
    William Blair
    More analyst ratings

    $CLYM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Ra Capital Management, L.P.

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    4/29/26 6:46:09 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thomas Stephen Basil sold $350,253 worth of shares (50,000 units at $7.01), decreasing direct ownership by 24% to 154,657 units (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    2/27/26 4:05:03 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thomas Stephen Basil sold $529,129 worth of shares (100,000 units at $5.29), decreasing direct ownership by 33% to 204,657 units (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    2/17/26 4:05:10 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

    WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal Association Congress 2026, which will be held in Glasgow, Scotland June 3-6, 2026. Climb Bio will present pharmacokinetic/pharmacodynamic modeling from nonhuman primates to humans for CLYM116, a novel ‘sweeper' anti-APRIL monoclonal antibody, which is being developed to treat IgA nephropathy (IgAN). Initial safety data from the ongoing CLYM116 Phase 1 study in healthy volunteers will also be presen

    5/26/26 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

    WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an upcoming presentation on its budoprutug program at the European Hematology Association (EHA) 2026 Congress, which will be held in Stockholm, Sweden June 11-14, 2026. Climb Bio will present data, including safety, B-cell depletion and initial platelet data from the low dose cohort (250mg at 24 weeks), from the ongoing Phase 1b/2a trial of budoprutug, a novel anti-CD19 monoclonal antibody, in previously treated patients with primary immune thrombocytopenia (ITP). Abstracts are av

    5/14/26 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio to Present at Upcoming Investor Conferences

    WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQFormat: Fireside ChatDate: Tuesday, May 19 Time: 11:00 – 11:30 a.m. ET Jefferies Global Healthcare Conference Format: Fireside ChatDate: Thursday, June 4 Time: 2:35 – 3:05 p.m. ET The live webcasts will be accessible via the "Investors & Media" section of the Climb Bio website. Webcast replays will be available on

    5/12/26 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $24,888 worth of shares (7,111 units at $3.50) (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    1/7/26 4:55:47 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. returned 20,440,000 shares to the company and bought $754,737 worth of shares (314,561 units at $2.40) (SEC Form 4)

    4 - Climb Bio, Inc. (0001768446) (Issuer)

    12/15/25 7:55:04 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CLYM
    SEC Filings

    View All

    Chardan Capital Markets initiated coverage on Climb Bio with a new price target

    Chardan Capital Markets initiated coverage of Climb Bio with a rating of Buy and set a new price target of $22.00

    5/5/26 7:04:06 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Climb Bio with a new price target

    Mizuho initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $18.00

    4/15/26 8:07:52 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Climb Bio with a new price target

    B. Riley Securities initiated coverage of Climb Bio with a rating of Buy and set a new price target of $26.00

    3/24/26 8:30:11 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Climb Bio Inc.

    S-3 - Climb Bio, Inc. (0001768446) (Filer)

    5/29/26 4:05:38 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Climb Bio Inc.

    10-Q - Climb Bio, Inc. (0001768446) (Filer)

    5/7/26 7:30:40 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Climb Bio, Inc. (0001768446) (Filer)

    5/7/26 7:05:16 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLYM
    Leadership Updates

    Live Leadership Updates

    View All

    Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

    WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Susan brings over two decades of strategic and financial leadership experience. "Susan is a seasoned biopharmaceutical leader with a strong track record in financial strategy, capital allocation, and operational execution, and we are delighted to welcome her to our team," said Aoife Brennan, President and CEO of Climb Bio. "Our company is making excellent progress advanci

    10/1/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

    Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

    6/18/25 7:00:00 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CLYM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Climb Bio Inc.

    SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)

    11/14/24 9:29:34 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care